Supported by grants from the Broad Medical Research Program (IBD-0253) and the National Institutes of Health (R56 AI089700) to B.J.C., and by an unrestricted educational grant from Wyeth Nutrition to L.W.
Version of Record online: 23 FEB 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 1, pages 112–119, January 2012
How to Cite
Wang, L., Trebicka, E., Fu, Y., Ellenbogen, S., Hong, C. C., Babitt, J. L., Lin, H. Y. and Cherayil, B. J. (2012), The bone morphogenetic protein–hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis, 18: 112–119. doi: 10.1002/ibd.21675
Conflicts of interest: H.Y.L. and J.L.B. have ownership interest in Ferrumax Pharmaceuticals, which has licensed technology from Massachusetts General Hospital based on their work. A patent application entitled “Methods and Composition to Regulate Iron Metabolism” has been submitted by Massachusetts General Hospital.
- Issue online: 11 DEC 2011
- Version of Record online: 23 FEB 2011
- Manuscript Accepted: 12 JAN 2011
- Manuscript Received: 5 JAN 2011
- bone morphogenetic protein;
A debilitating anemia associated with low serum iron often accompanies inflammatory bowel disease (IBD). Increased production of the iron regulatory hormone hepcidin is implicated in its pathogenesis and may also contribute to the inflammatory process itself. Hepcidin expression is dependent on bone morphogenetic proteins (BMPs) like BMP6, but the mechanisms that increase hepcidin levels during intestinal inflammation are not clear. Here we test the hypothesis that inhibiting hepcidin expression may have beneficial effects in IBD, and also shed light on the mechanism of colitis-induced hepcidin upregulation.
Mice with T cell transfer colitis were treated with vehicle or one of three anti-BMP reagents: HJV.Fc, a recombinant protein that prevents binding of BMPs to their receptor, LDN-193189, a small molecule inhibitor of BMP signal transduction, and an anti-BMP6 antibody. The effects of these reagents on colitis severity, liver hepcidin mRNA, and serum iron were determined. The mechanism of hepcidin upregulation was investigated by examining BMP6 expression and activity and the effects of IL-6 deficiency.
All the anti-BMP reagents inhibited hepcidin expression and increased serum iron levels in the colitic mice. They also produced modest reductions in colon inflammatory cytokine expression. Although hepcidin upregulation during colitis was dependent on BMP6, it was not associated with increased BMP6 expression or activity. IL-6 was required for increased hepcidin expression during colitis.
Inhibiting hepcidin expression may help to correct the anemia of IBD and may also attenuate intestinal inflammation. The mechanism of colitis-induced hepcidin upregulation involves both BMP6 and IL-6. (Inflamm Bowel Dis 2011)
Inflammatory bowel disease (IBD) can be complicated by the development of an iron deficiency anemia that is only partly explained by intestinal blood loss. This so-called anemia of chronic disease (ACD) is seen in association with other inflammatory conditions, is often refractory to oral iron supplementation, and may require treatment with parenteral iron or erythropoietin.1 Understanding ACD pathogenesis has been of considerable interest to clinicians and basic researchers, especially since it can have a significant impact on quality of life. Recent elucidation of the mechanisms that regulate iron metabolism have shed light on the condition, and have revealed an important role for hepcidin, an iron-regulating hormone secreted by hepatocytes.2, 3
Hepcidin controls the amount of iron entering the circulation by binding and downregulating ferroportin, a plasma membrane transporter that pumps iron out of phagocytes and duodenal enterocytes, the sites where iron is recycled from aged red blood cells and absorbed from the diet, respectively.2, 4 Hepcidin expression is regulated transcriptionally in response to changing serum iron levels. Elevated serum iron promotes hepcidin expression, leading to downregulation of ferroportin and decreased entry of iron into the circulation. Conversely, low serum iron leads to reduced hepcidin expression, elevated ferroportin, and increased movement of iron into the circulation. A key molecule involved in sensing serum iron and regulating hepcidin expression appropriately is HFE, an atypical class I major histocompatibility protein expressed on the hepatocyte surface.5–7 The HFE–hepcidin–ferroportin axis functions as a central mechanism for maintenance of iron homeostasis. Mutations in the HFE gene are associated with the most common inherited iron overload disorder in humans, type I hereditary hemochromatosis.5, 8 Recent work has shown that hepcidin transcription depends on functional interactions between signals induced by HFE and those activated by bone morphogenetic proteins (BMPs) such as BMPs 2, 4, and 6.9–12 The binding of these BMPs to their receptor and the coreceptor hemojuvelin (HJV) expressed on hepatocytes initiates a cascade of events, including the phosphorylation of the receptor SMADs 1, 5, and 8, that culminate in the transcriptional upregulation of the hepcidin gene. Of the various BMPs, BMP6 appears to be the most functionally relevant regulator of hepcidin in vivo: its expression is modulated by circulating iron levels and its absence in mice leads to marked iron overload.13–15
In addition to iron status, inflammatory cytokines can also influence transcription of the hepcidin gene. Interleukin-6 (IL-6) has been shown to increase hepcidin expression in vitro and in vivo, and IL-6-induced hepcidin upregulation has been proposed to play an important role in the pathogenesis of ACD.16–18 The properties of hepcidin are consistent with this role. The decrease in ferroportin expression that results from elevated hepcidin levels would block entry of iron into the circulation, with consequent impairment of erythropoiesis.3, 16 Furthermore, since intestinal absorption of iron is inhibited by the hepcidin-mediated downregulation of ferroportin on enterocytes, the anemia would be resistant to oral iron supplementation. Although the importance of IL-6 in inducing hepcidin expression has been demonstrated in tissue culture experiments and in relatively simple in vivo models of inflammation such as the injection of lipopolysaccharide (LPS) or turpentine,16–18 the mechanisms that upregulate hepcidin in more clinically relevant situations, including IBD, are yet to be worked out.
We have shown recently that besides acting as a key regulator of iron homeostasis, hepcidin may also contribute to the pathogenesis of inflammatory states. In Hfe knockout mice, a model of human type I hemochromatosis,19 we found that abnormally low expression of hepcidin was associated with attenuated Salmonella enterocolitis in vivo and reduced LPS-induced production of inflammatory cytokines by peritoneal macrophages in vitro.20, 21 The decrease in cytokine production by the mutant macrophages was caused by the low intracellular iron in these cells, which in turn was the result of elevated ferroportin expression secondary to the impaired hepcidin expression in the mice.20 In keeping with these observations, treatment of Hfe-deficient and wildtype macrophages with either hepcidin or ferrous sulfate enhanced their expression of inflammatory cytokines in response to LPS stimulation.21 Based on the data, we proposed that hepcidin might contribute to the development of a positive feedback loop in which inflammatory cytokines induce hepcidin upregulation, the hepcidin downregulates ferroportin, and the consequent increase in intracellular iron in macrophages promotes the production of inflammatory cytokines.21, 22 We suggested that blocking hepcidin expression could represent a way to interrupt this vicious cycle and thereby correct the dysregulated iron metabolism associated with inflammatory states such as IBD and also have beneficial effects on maladaptive inflammation. We obtained preliminary support for this idea by using broad-spectrum inhibitors of BMPs in the Salmonella enterocolitis and piroxicam/IL-10 knockout colitis models.21 In the present work we investigated the effects of these inhibitors, as well as a more selective strategy of BMP6 neutralization, in T cell transfer colitis, which is generally considered to be the mouse model of intestinal inflammation most similar to human IBD.23 We also carried out studies to elucidate the mechanism by which hepcidin is upregulated during colitis.
MATERIALS AND METHODS
All animal experiments were approved by the Sub-committee on Research Animal Care of Massachusetts General Hospital.
Induction of T cell Transfer Colitis
We used a version of the T cell transfer colitis model based on previously published protocols.23 In brief, naïve CD4+CD25− T cells were purified from the spleens of 6–8-week-old wildtype C57BL/6 male mice (Jackson Laboratory, Bar Harbor, ME) using a magnetic sorting-based purification kit as per the manufacturer's directions (Miltenyi Biotec, Auburn, CA). The isolated cells were suspended in phosphate-buffered saline (PBS) and injected intraperitoneally into 6–8-week-old, male, lymphocyte-deficient recipient mice (C57BL/6 background), so that each mouse received 1–2 million cells. Depending on availability, we used either RAG1 or RAG2 knockout mice as recipients, the former being from a breeding colony at Massachusetts General Hospital and the latter from Taconic (Hudson, NY). All recipient mice were of the same genotype in any given experiment. The clinical status and body weight of the animals were monitored over the succeeding 6–8 weeks.
Treatment of Mice
Treatment with inhibitors of BMP-dependent hepcidin expression was initiated 6 weeks after transfer of T cells. Three different treatment protocols were used, with all therapeutic reagents being administered intraperitoneally: 1) purified recombinant HJV.Fc fusion protein, prepared as described previously,9, 10 15 mg/kg body weight per dose, 3 doses per week for 2 weeks; 2) the small organic compound LDN-193189 (synthesized at the Vanderbilt Institute of Chemical Biology), a dorsomorphin analog,21, 24 3 mg/kg body weight, 2 doses per day for 1 week; 3) a neutralizing anti-BMP6 antibody (R&D Systems, Minneapolis, MN),13 10 mg/kg body weight, 3 doses per week for 2 weeks. Control mice were injected at the same times with an equivalent volume of vehicle (2% 2-hydroxypropyl-β-cyclodextrin in the case of LDN-193189 and PBS in the case of the HJV.Fc and anti-BMP6). The animals were euthanized by carbon dioxide asphyxia at the end of the treatment period.
Analysis of Hepcidin and BMP6 Expression
At necropsy, a piece of liver was excised and total RNA prepared using Trizol reagent as directed by the manufacturer (Invitrogen, Carlsbad, CA). Quantitative reverse-transcription polymerase chain reaction (RT-PCR) was carried out as previously described20, 21 with primers specific for hepcidin and BMP6. Relative expression was calculated using the 2−ΔΔCt method with normalization to GAPDH. We have published the primer sequences for hepcidin and GAPDH previously.20, 21 The primers used to amplify BMP6 mRNA were 5′ATGGCAGGACTGGATCATTGC3′ and 5′CCATCACAGTAGTTGGCAGCG3′.25
Evaluation of Colitis
At necropsy, the colon was excised and its length measured. Segments of the proximal, middle and distal colon were processed for hematoxylin/eosin staining and histopathological analysis, and for measurement of cytokine mRNA levels by quantitative RT-PCR, all as previously described.20, 21 The colon histopathology was assigned an inflammation score21 by an observer who was unaware of treatment status. The primers used for amplification of IL-17 transcripts were 5′CCACGTCA CCCTGGACTCTC3′ and 5′CTCCGCATTGACACAGCG3′.26 Relative expression was calculated using the 2−ΔΔCt method with normalization to GAPDH.
Analysis of Serum Iron Concentration
Serum iron concentrations were measured as described previously10 using a colorimetric assay from Thermo Scientific (West Palm Beach, FL).
Treatment with Dextran Sulfate Sodium (DSS)
Mice were given 2.5% DSS (molecular weight 36,000–50,000, MP Biomedicals, Solon, OH) in drinking water ad libitum and were euthanized 48 hours after start of treatment. In these experiments, the mice were injected with anti-BMP6 or vehicle as described above, with the first dose being given just prior to start of DSS and a second dose 6 hours before euthanasia. In the experiments examining IL-6 expression, the period of DSS treatment was extended to 7 days for some of the mice.
Fragments of liver were homogenized in radioimmunoprecipitation assay (RIPA) buffer containing a cocktail of protease and phosphatase inhibitors, separated by polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes, all as described previously.27 The membranes were blocked and probed with antibodies to phospho-SMAD1/5/8 and total SMAD1 (Cell Signaling Technology, Danvers, MA). After developing the blots with the appropriate fluorescently labeled secondary antibody reagents, they were visualized using the Li-Cor Odyssey infrared imaging system (Li-Cor Biotechnology, Lincoln, NE). The intensities of the phospho-SMAD bands were quantified and normalized to the corresponding total SMAD1 bands.
The means and standard deviations of the results from multiple animals are shown. Student's t-test was used to determine significance, with P < 0.05 considered significant.
The experimental scheme used in our studies is illustrated in Figure 1A. Using the magnetic sorting protocol, we obtained 80%–90% pure CD4+CD25− naïve T cells for injection into RAG-deficient recipients (Fig. 1B). Initial experiments revealed that changes in body weight were not a reliable indicator of colitis, so we chose 6 weeks after T cell transfer, when most animals had developed appreciable intestinal inflammation, as the standard time to initiate treatment. None of the treatments used altered body weight, or the gross appearance, histopathology, or tissue inflammation score of the colon, so these results will not be presented.
RAG-deficient mice that received naïve T cells and that were treated with vehicle expressed significantly higher levels of hepcidin in the liver than control animals that did not receive T cells (Fig. 2A). This upregulation corresponded to increased colonic levels of the inflammatory cytokines IL-17 (Fig. 2B) and IL-6 (not shown), indicative of colitis. Treatment of the colitic mice for 2 weeks with HJV.Fc, a soluble form of the BMP coreceptor HJV that blocks binding of BMPs 2, 4, and 6 to their receptor,9, 10 successfully inhibited hepcidin upregulation (Fig. 2A), and also significantly decreased IL-17 mRNA levels in the middle and distal segments of the colon (Fig. 2B). The HJV.Fc treatment also significantly elevated serum iron concentrations (Fig. 2C).
We repeated the experiment with two other inhibitors of BMP-induced hepcidin expression: the small organic compound and dorsomorphin analog LDN-193189, which blocks intracellular signaling pathways activated by BMPs,24 and an antibody that specifically neutralizes BMP6. Because of the twice-daily dosing required for LDN-193189, we limited its use to 1 week of treatment, whereas the anti-BMP6 antibody was used for 2 weeks. The results are shown in Figures 3 and 4. Each of the two reagents inhibited hepcidin expression in the mice with T cell transfer colitis (Figs. 3A, 4A) and increased serum iron concentrations (Figs. 3C, 4C). They also had modest and variable effects on the severity of intestinal inflammation, as indicated by decreases in tissue IL-17 mRNA levels (Figs. 3B, 4B). Even though these experiments indicated a clear requirement for BMPs, and for BMP6 in particular, for the upregulation of hepcidin associated with intestinal inflammation, there was no increase in BMP6 expression in the animals with T cell transfer colitis (Fig. 5).
To gain mechanistic insight into the role played by BMP6 in intestinal inflammation-induced hepcidin upregulation, we turned to the DSS colitis model. We found that hepcidin expression was significantly increased 48 hours after starting DSS, and that the upregulation was inhibited by treatment with the BMP6 neutralizing antibody (Fig. 6A). However, there was no change in BMP6 mRNA levels associated with the DSS-induced hepcidin upregulation (Fig. 6B). BMP2 and BMP4 levels were also not affected by the DSS treatment (data not shown). Furthermore, we could not detect evidence of activation of BMP-dependent signaling in the liver as assayed by immunoblotting with an antibody specific for the phosphorylated forms of SMADs 1, 5, and 8 (Fig. 6C,D).28 Thus, the BMP6-dependent increase in hepcidin expression associated with colitis occurred without overt indications of an increase in BMP6 expression or activity.
Since IL-6 has been implicated in upregulation of hepcidin in LPS- and turpentine-induced models of inflammation,16–18 we examined expression of this cytokine in the colon and liver and found an increase in both tissues by 48 hours after starting DSS, and a more significant elevation at the end of 1 week (Fig. 7A). Consistent with the functional importance of this observation, the DSS-induced increase in hepcidin expression was significantly reduced in IL-6 knockout animals (Fig. 7B). Our results suggest that IL-6 is an important inducer of hepcidin upregulation in the context of intestinal inflammation.
The results reported here make several important points relevant to the pathogenesis and treatment of IBD, especially in relation to the dysregulated iron metabolism and ACD that is often associated with this condition.1 First, they demonstrate that intestinal inflammation in T cell transfer colitis and in DSS-induced colitis is associated with a significant increase in hepcidin expression in the liver. This finding is consistent with earlier work from our laboratory, which showed a similar upregulation of hepcidin in piroxicam/IL-10 knockout colitis, as well as in Salmonella-induced enterocolitis.21 Thus, multiple forms of intestinal inflammation, including that occurring in three different mouse models of IBD, lead to the induction of hepcidin expression. Hepcidin upregulation has also been observed in at least some, although not all, studies of human IBD. Semrin et al29 found in an analysis of pediatric Crohn's disease that urinary hepcidin levels were elevated in individuals with active inflammation. In contrast, a study of adult patients with ulcerative colitis or Crohn's disease found decreased serum levels of hepcidin.30 The variable results suggest that hepcidin upregulation in human IBD is likely to be influenced by factors such as age, type of disease, and disease activity, and that further investigation of these issues is required.
Our findings also indicate that elevated hepcidin contributes to two aspects of the disease process in T cell transfer colitis, viz., the dysregulated iron metabolism and the inflammation. Blocking hepcidin expression with three different inhibitors led in all cases to a significant elevation of serum iron levels, confirming and extending similar observations that we made earlier in the Salmonella enterocolitis and piroxicam/IL-10 knockout colitis models.21 This outcome fits with the known role of hepcidin as an inhibitor of ferroportin-mediated iron export from phagocytes and enterocytes,2–4 and is in keeping with results from one study of human IBD that showed that patients with active Crohn's disease had impaired oral absorption of iron.29 Taken together, the data suggest that elevated hepcidin is likely to be a significant factor in the pathogenesis of ACD in IBD. Blocking hepcidin expression also attenuated the severity of intestinal inflammation in our experiments, at least to the extent of reducing tissue inflammatory cytokine expression. The effect on inflammation was not as pronounced as in our earlier work with the Salmonella enterocolitis and piroxicam/IL-10 knockout colitis models.21 The difference may reflect the fact that those models are driven mainly by innate immune mechanisms, whereas T cell transfer colitis is mediated by adaptive immunity.23, 31–33 This issue could be especially relevant since the effects of hepcidin on the immune response appear to be mediated mainly by macrophages.21 Another factor that could contribute to the variable effects of inhibiting hepcidin expression on inflammation is the recent observation that hepcidin may downregulate inflammatory cytokine production under some circumstances. Studies by De Domenico et al34 showed that the binding of hepcidin to ferroportin can activate a signaling cascade, involving the Jak2 kinase and the STAT3 transcription factor, which suppresses LPS-induced expression of a number of cytokines. Thus, the hepcidin–ferroportin interaction may influence macrophage cytokine expression negatively via Jak2/STAT3 signaling, as shown by the experiments of De Domenico et al, or positively via an increase in intracellular iron, as indicated by our studies, and the net outcome of blocking hepcidin expression on the inflammatory response may depend on which of these effects predominates.
In addition to demonstrating the important role played by hepcidin in colitis, our experiments have provided insight into the mechanisms that induce hepcidin during intestinal inflammation. The results indicate that of the several BMPs that have been implicated as regulators of hepcidin expression,9, 10, 13 BMP6 clearly plays an essential role in the context of the colitis models used here since neutralization of this molecule alone significantly reduced hepcidin levels. Interestingly, intestinal inflammation was not associated with increases in liver BMP6 mRNA levels or BMP6-dependent signaling activity in our studies. These results suggest that even though BMP6 was required for normal expression of hepcidin, the actual stimulus for colitis-induced hepcidin upregulation involved another factor. Our findings point to increased production of IL-6 by the liver and other tissues during colitis as being one such factor. The data suggest a mechanism in which signals activated by increased IL-6 expression interact with constitutive signals provided by basal levels of BMP6 to promote hepcidin transcription. The combination of the two sets of signals determines the amount of hepcidin expressed and blocking either leads to lowering of hepcidin production. This explanation is consistent with earlier observations showing that an intact BMP-SMAD pathway is required for IL-6-induced hepcidin upregulation and that signals activated by BMPs and IL-6 probably interact at the level of the hepcidin promoter.10, 24, 35, 36 Moreover, BMP6-deficient mice have abnormally low basal hepcidin production, and although they upregulate expression following LPS exposure, the final level achieved is significantly lower than wildtype animals.14 On the other hand, IL-6 knockout mice have normal basal hepcidin levels but fail to upregulate expression following LPS stimulation.16
The data presented here, along with our earlier findings,21 demonstrate that lowering abnormally elevated levels of hepcidin has a beneficial effect on serum iron in multiple models of colitis, probably as a result of increased ferroportin-mediated release of iron into the circulation. Thus, inhibiting hepcidin expression or function in inflammatory conditions such as IBD is likely to be helpful in correcting the associated anemia by facilitating the absorption and recycling of iron. This approach could represent a novel therapeutic strategy for the ACD associated with chronic inflammation, one that our results suggest may have the added benefit of helping to attenuate the inflammatory process itself. Treatment of ACD based on hepcidin modulation could be especially relevant to IBD since the oral administration of iron in this condition may exacerbate the intestinal inflammation.1, 37–41 Further investigation of these ideas is clearly indicated.
We thank the Chemical Synthesis Core, Vanderbilt Institute of Chemical Biology for synthesizing the LDN-193189, and Dr. Hai Ning Shi, Massachusetts General Hospital, for advice on some of the experiments.